Skip to main content
Premium Trial:

Request an Annual Quote

Claritas Genomics Receives NY State Approval for Dx Tests

NEW YORK (GenomeWeb) – Claritas Genomics announced today that it has received New York State Department of Health approval to start offering its Clinical Exome and Pediatric Neurology Region of Interest diagnostic tests in New York.

The company — which was created by Boston Children's Hospital and Cincinnati Children's Hospital in partnership with Cerner, Wuxi NextCode Genomics, and Thermo Fisher Scientific — offers the Clinical Exome test for people with complex, multi-systemic symptoms, or conditions with genetic and phenotypic heterogeneity.

The Pediatric Neurology Region of Interest focuses on eight neurological regions, including neuromuscular disorders, movement disorders, epilepsy and seizures, brain malformations, developmental delay and intellectual disability, hereditary peripheral neuropathy, leukodystrophy and encephalopathy, and autism.

Both tests use Claritas' dual-capture, dual-sequencing platform method.

"New York State is known for having a rigorous evaluation process," Claritas Chief Operating Officer Mary Ellen Cortizas said in a statement. "Today's approval is a key component of our quality and regulatory strategy."

The company's clinical laboratories are also CLIA and ISO 15189 certified, Claritas noted.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.